AstraZeneca has agreed a deal to acquire EsoBiotec for up to £750m. The acquisition includes the Belgian firm’s in vivo delivery platform, which the Cambridge pharma giant said has the potential to transform cell therapy. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients … Continue reading AstraZeneca agrees £750m deal for EsoBiotec